Introduction
The diagnosis of antibody-mediated rejection (ABMR) is associated with poor renal allograft survival [1, 2] . The increased recognition of ABMR as a major cause of graft loss is mainly driven by the advent of better techniques to identify donor-specific HLA antibodies (DSA) [3] . Among renal allograft recipients, the frequency of HLA antibodies (HLAabs) in serum ranges between 20 and 30% [4, 5] . In addition, antibodies against MHC class I-related chain A (MICA) antigens [6] and angiotensin II type 1 (AT1) receptor-activating antibodies [7] may also cause ABMR. Up until recently, treatment protocols for ABMR were mainly based on plasmapheresis (PPH) [8] , the administration of intravenous immunoglobulin (IVIG) preparations or a combination of both [9] . The dose of IVIG varies between 0.1 g/kg (low dose), given after each PPH [10] and 1-2 g/kg (high dose), given as monotherapy [11] or together with PPH [12] .
In the more recent era, two compounds, more specifically targeting B cells and plasma cells, became available: rituximab (MabTheraÒ), a B-cell-depleting monoclonal antibody directed against CD20 and bortezomib (VEL-CADE Ò ), a proteasome inhibitor causing apoptosis of plasma cells. Rituximab is a chimeric monoclonal antibody directed against CD20, which is found on immature and mature B cells but not on plasma cells. Following treatment with rituximab, B cells undergo apoptosis and lysis. Most adverse events are first infusion effects of generally mild severity. Additionally, an increased incidence of infections has been described including cases of progressive multifocal leukoencephalopathy [13] . In renal transplantation, rituximab is used for the treatment of ABMR as well as for desensitization of highly sensitized patients [14] or patients awaiting ABO-incompatible renal transplantation [15] . Kaposztas et al. [16] investigated 54 patients with ABMR and found that the addition of rituximab to PPH improved 2-year graft survival post-diagnosis. Lefaucheur et al. [17] reported that graft survival at 36 months was superior in patients treated with a combination of PPH followed by daily low-dose IVIG, high-dose IVIG after the last PPH and rituximab as compared to patients treated with high-dose IVIG only. Mulley et al. [18] observed that a single fixed dose of 500 mg rituximab in addition to PPH and low-dose IVIG resulted in resolution of ABMR. Rostaing et al. published several reports on the treatment of acute ABMR [19, 20] , suggesting that rituximab in addition to steroid pulse treatment and PPH may be an effective regimen. However, patients experienced 'numerous serious infections' and 2/22 patients even died due to severe infection [20] , probably due to combined treatment with T-cell-depleting antibodies.
The proteasome inhibitor bortezomib, which affects mature plasma cells, is a new approach to treat ABMR. Everly et al. [21] described six patients with mixed ABMR and acute cellular rejection, who were treated with one to two cycles of bortezomib in addition to varying doses of methylprednisolone, ATG, rituximab and PPH. They observed prompt reversal of rejection and prolonged reduction of DSA levels. Perry et al. [22] showed in vitro that bortezomib caused plasma cell apoptosis and blockade of anti-HLA IgG secretion. Treatment of ABMR in two patients with bortezomib, PPH and IVIG resulted in a decrease of HLAab levels. Renal function at 1-year post-transplant was excellent. Trivedi et al. [23] described a substantial decrease of HLAab levels in 9/11 patients after treatment with bortezomib, PPH, methylprednisolone and one dose of rituximab (6/11 patients). In contrast, Sberro-Soussan et al. [24] observed that one cycle of bortezomib did not significantly decrease DSA levels within 150 days after treatment in four patients. Flechner et al. [25] reported recently that a bortezomib-containing regimen including methylprednisolone, PPH and IVIG is most effective when treatment is initiated before the onset of renal dysfunction.
Taken together, current evidence indicates that treatment with rituximab or bortezomib may help to improve the prognosis of patients with ABMR, although some results are conflicting and long-term outcome data are sparse. The fact that varying dosages in varying treatment regimens (AE steroids AE PPH AE IVIG AE ATG) were used and that no control group was included in a substantial part of these studies makes it difficult to draw clear cut conclusions for specific treatment protocols. In order to compare the efficacy of both compounds, we treated 10 consecutive renal allograft recipients with biopsy-proven ABMR with one cycle of bortezomib in addition to our standard regimen (PPH 1 IVIG) starting in February 2009. This group was compared to a historical control group of nine patients, who had received the same standard regimen in combination with a fixed dose of rituximab. Both groups were followed for a minimum of 18 months in order to have a reasonably long-term follow-up on safety and efficacy.
Materials and methods
Renal transplantation was carried out at the Charité hospital based on a negative complement-dependent cytotoxicity crossmatch (CDC-XM) with and without dithiothreitol using T and B lymphocytes with current and historical serum. Flow cytometric crossmatches were not performed. However, graft allocation was based on a negative virtual crossmatch by considering unacceptable antigens as defined by solid phase assays (ELISA and Luminex). All patients presented with clinically relevant allograft dysfunction post-transplant manifesting as an otherwise unexplained increase of serum creatinine (!0.3 mg/dL), proteinuria (!1 g/day) or primary non-function in the early phase after transplantation. Each patient had a for-cause renal biopsy demonstrating ABMR in the absence of T-cell-mediated rejection. Renal allograft pathology was carried out by an experienced pathologist (B.R.). The diagnosis of ABMR was based on the presence of circulating HLA-DSA and/or anti-MICA antibodies (MICAabs) and significant allograft pathology according to the definitions of the most recent Banff classification [26, 27] . C4d staining was done by indirect immunofluorescence using a polyclonal rabbit anti-human C4d IgG antibody (Biomedica, Vienna, Austria). A linear circumferential staining pattern of the peritubular capillaries was considered as positive. Only patients who gave their written informed consent were considered eligible for treatment with either rituximab or bortezomib.
Serum samples before and after treatment were screened for HLAabs and MICAabs by the Luminex bead-based assay LABScreenÒ Mixed (LSM) (One Lambda, Canoga Park, CA). In addition, HLAab specificities were determined by LABScreenÒ Single Antigen beads assay (One Lambda). Due to missing MICA typing of recipient and donor, specificity of MICAabs was not determined. All tests were performed according to the product insert issued by the manufacturer. As an indicator for the antibody level, the normalized mean fluorescence intensity (MFI) was used. HLAabs were considered positive when showing an MFI value >500. Alternatively, for normalization purposes, %MFI was calculated according to the following equation: In addition, all patients underwent six sessions of PPH (2.5 L/session, 4% albumin) and received 30 g of polyvalent human IVIG (KIOVIGÒ) after the last PPH. This group was compared to a historical control group of all patients with biopsyproven ABMR treated with a single dose of rituximab (500 mg i.v.) and the same protocol of six PPH sessions (2.5 L/session, 4% albumin) and 30 g polyvalent IVIG at our centre (n ¼ 9). Patients of the control group were treated between March 2005 and December 2008. All patients with acute ABMR additionally received three methylprednisolone pulses (500 mg/day). After discharge, patients were regularly seen in our outpatient clinic. These visits included therapeutic drug monitoring and dose adjustments, if necessary.
Renal allograft survival was defined as the interval between treatment of ABMR and resumption of chronic dialysis. Glomerular filtration rate was calculated using the chronic kidney disease epidemiology collaboration formula [28] . Comparison between the two groups was carried out using Fisher's exact test for categorical variables and the Mann-Whitney U-test for continuous variables. Graft survival was analysed according to Kaplan-Meier with a log-rank test. A probability of <0.05 was considered as statistically significant.
Results
Patient characteristics (Table 1) were similar in both groups, except that donors and recipients were older in the rituximab group. In all patients, DSA and/or MICAabs were present. Maintenance immunosuppression at the time of diagnosis and after diagnosis is also shown in Table 1 . One patient in the bortezomib group received steroid monotherapy (methylprednisolone 20 mg/day) at diagnosis. In this patient, maintenance immunosuppression with everolimus and mycophenolic acid was stopped 2 weeks before the occurrence of ABMR because of severe life-threatening pneumonia. Following diagnosis, all patients received triple maintenance immunosuppression. One patient in each group was converted to tacrolimus after diagnosis.
Patient survival at 18 months after treatment was 100% in both groups. In the bortezomib group, we observed a high incidence of reversible thrombocytopenia, which was mild (Grade I) in five patients and severe (Grade III) but clinically silent in two patients with pre-existing thrombocytopenia. Two patients suffered from infection of the central venous catheter, which was inserted to carry out PPH. In both patients, symptoms disappeared after exchange of the catheter and start of antibiotic treatment. One patient experienced culture-negative spontaneously reversible diarrhoea, one patient had spontaneously reversible diffuse abdominal pain without any objective focus and one patient had fever of unknown origin, which was reversible upon empiric antibiotic therapy. Following treatment with rituximab, peripheral CD191 B cells were no longer detectable for at least 6 months (data not shown). In patients treated with rituximab, severe leucopaenia (Grade III) was observed in three patients and mild thrombocytopenia (Grade I) in one patient. Three patients experienced an episode of urinary tract infection and one patient acute otitis media. All of them responded to antibiotic treatment.
At 18 months after treatment, graft survival in the bortezomib group was superior to the rituximab group (60 versus 11.1%, P ¼ 0.071) (Figure 1 ). In the bortezomib group, 4/7 grafts with acute and 0/3 grafts with chronic ABMR failed during the observation period. In comparison, 5/6 grafts with acute and 3/3 grafts with chronic ABMR failed in the rituximab group. The only patient of the rituximab group with functioning graft at 18 months after treatment returned to chronic dialysis at 54 months after treatment. Renal function of the patient mentioned above, who experienced ABMR while being on steroid monotherapy, did not recover following bortezomib treatment. He returned to chronic dialysis treatment within 1 month after diagnosis. At 9 months after treatment, mean serum creatinine (2.5 AE 0.6 versus 5.1 AE 2.1 mg/dL, P ¼ 0.008) as well as the mean estimated glomerular filtration rate (31.1 AE 9.5 versus 12.3 AE 4.7 mL/min, P ¼ 0.028) was better in the bortezomib group as compared to the rituximab group (Figure 2A) . Due to the small number of patients with functioning graft in the rituximab group at >9 months after treatment (n 2) differences in renal function between both groups were not calculated at this stage. Proteinuria of >1 g/day prior to treatment was present in 5/10 patients of the bortezomib and in 4/9 patients of the rituximab group, respectively. No significant differences between both groups were found concerning the amount of proteinuria ( Figure 2B ). Transplant glomerulopathy was diagnosed in 8/10 patients of the bortezomib group and in 4/9 patients of the rituximab group (P ¼ 0.170).
The majority of patients in the bortezomib and rituximab group showed HLA class II DSA with an incidence of 9/10 and 6/7, respectively. In most cases, these HLA class II DSA were accompanied by HLA class I DSA (i.e. 6/9 and 3/6, respectively). All reported DSA have been produced de novo post-transplant. Antibodies' donor specificity was determined solely based on patient and donor typing for HLA-A, -B, -DRB and -DQB. MICAabs were tested by the screening test but not specified. Therefore, MICA antibody . In patients treated with bortezomib in addition to standard therapy (n ¼ 10), graft survival at 18 months after treatment was 60% as compared to 11% in patients who received rituximab in addition to standard therapy (n ¼ 9). levels were not quantified. The course of the level of DSA (either HLA class I or class II) with the highest MFI values before treatment (DSAmax) is shown in Figure 3 . In both groups, the DSAmax was mainly directed against HLA class II antigens. Only patients B3, B4 and B10 from the bortezomib and R7 from the rituximab group revealed class I HLAabs as DSAmax. The starting MFI values of the DSAmax as the indicator for antibody levels pre-treatment varied substantially between 648 and 19 827 MFI (median 7764 MFI) among the bortezomib-and between 498 and 17 169 MFI (median 8100 MFI) among the rituximab-treated patients. There was no correlation between either the starting %MFI or MFI value and the success of treatment in decreasing DSAmax levels. Among the bortezomib group, 4/4 with starting %MFI >150 (high) and 4/6 with %MFI <150 (intermediate to low) as well as 4/4 with starting MFI >10 000 and 4/6 with MFI <10 000 showed a decrease in DSAmax levels after treatment (P ¼ 0.47 and P ¼ 0.47, respectively). Correspondingly, among the rituximab group, the proportions were 3/4 and 2/3 (P ¼ 0.52) as well as 2/3 and 3/4 (P ¼ 0.52), respectively. No difference between both groups was found concerning the occurrence of a sustained decrease of DSAmax levels after treatment (%MFI: 5/10 versus 4/7, P ¼ 1.0 and MFI: 5/10 versus 4/7, P ¼ 1.0). The bystander DSA and non-donor-specific HLAabs behaved very similarly (data not shown). None of the applied treatment regimens was able to completely abolish DSAmax levels. The maximum decrease was noted for patient B5 with a decline of 164 pp starting from 255 %MFI (i.e. 18 170 MFI) down to 91 %MFI (i.e. 5600 MFI). The average decrease was 85 AE 62 pp for both groups.
Although DSAmax levels could be reduced in 13/17 patients (76%), the percent virtual panel reactivity remained mainly unaltered for most patients (82%) as shown in Table 2 . Nevertheless, a sustained decrease in DSAmax levels was predictive for better graft outcome within 18 months after treatment among the bortezomib-treated patients. Graft loss was noted for 0/5 patients with sustainably declining DSAmax levels but 4/5 with unaltered or transiently decreasing DSAmax levels (P ¼ 0.048). There was no such effect notable for rituximabtreated patients with proportions of 4/4 and 2/3 patients (P ¼ 0.43), respectively.
Discussion
Since the first reports on usage of bortezomib and rituximab as antihumoral rejection therapeutical clinicians have been keen to use these agents in the treatment of ABMR. Here, we compared a group of 10 consecutive kidney transplant recipients with biopsy-proven ABMR, which underwent antihumoral rejection therapy by bortezomib in conjunction with PPH and IVIG, with a historical control group of nine patients, who received rituximab plus the same dose of PPH and IVIG. Patients with acute ABMR additionally received one cycle of methylprednisolone pulse therapy.
Concerning the relevant patient characteristics, both groups are well comparable. In our view, the existing age difference between both groups is of minor importance because renal function before the occurrence of ABMR was not different between both groups. In addition, the type (acute versus chronic) and grade of acute rejection episodes were not different between both groups. Taken together, treatment with the bortezomib protocol was partly effective, whereas the applied rituximab protocol did not result in satisfactory outcomes, although peripheral B cells were not detectable for at least 6 months after treatment with rituximab. A reasonable explanation for the inferior graft survival of the rituximab group in comparison to the existing literature seems to be that we used a very strict definition of ABMR, whereas circulating DSA [16, 18, 19] as well as histological signs of ABMR [16] were not present in all patients included in other studies. In addition, we employed a less aggressive immunosuppressive treatment regimen than most other studies, which included higher doses of rituximab [16, 17, 19, 20] , higher doses of IVIG [17, 18] , more PPH sessions [16, 18, 19] , the addition of Tcell-depleting antibodies [16, 19, 20] and even splenectomy [17] . Nevertheless, it is important to report that a single fixed dose of rituximab was not able to treat ABMR effectively.
Both regimens were generally well tolerated and all participants are currently in good health. The most prominent adverse event in rituximab-treated patients was reversible leucopaenia (3/9 patients), which was associated with infection (otitis media) in one patient. Three patients developed urinary tract infection in the absence of leucopaenia. In comparison, the majority of patients (7/10) treated with bortezomib experienced reversible thrombocytopenia without evidence for bleeding. Two patients in this group suffered from gastrointestinal side effects resolving spontaneously. Three patients had infections, all of them responded to antibiotic treatment. Levels of anti-HLAabs were measured before and after treatment with today's most sensitive HLAab detection assay. Using beads, each coated with a single recombinant HLA antigen, this assay allowed us to clearly identify the HLA specificity of an antibody. Although knowing that the MFI value does not directly reflect the antibody titre, it was used here as the most appropriate way to estimate DSA levels. Due to the high sensitivity and due to the fact that serum is a crude biological medium containing diverse interfering substances (proteins, blocking IgM etc), the MFI is known to vary from sample to sample. Calculating %MFI, we considered the MFI range between the internal positive and negative control bead as an indicator of unspecific interference of serum substances with the HLA-coated beads. By this means, the unspecific background for each individual sample is normalized and MFI values are more comparable. Interestingly, the relative decrease of DSA levels after treatment but not the absolute value of DSA at diagnosis seems to predict the success of treatment among the group of patients treated with bortezomib. The prognosis for 18-month graft survival after treatment was excellent for patients revealing a sustained decline in DSAmax levels independently from the absolute MFI value at the time of diagnosis. The only patient (B3) with functioning graft after 18 months without a sustained decrease in DSAmax levels displayed very low DSAmax levels throughout the whole observation period. There was no such effect notable for patients, who underwent a rituximab-based therapy. Four patients had only a transient decline in DSAmax levels, and all experienced a strong recurrence after treatment. Absolute MFI values were even higher than at the time of diagnosis, and all four patients lost their graft during follow-up.
Our results indicate that treatment of ABMR with the applied bortezomib regimen is superior to the applied rituximab regimen. However, even the bortezomib regimen was not sufficient to treat all episodes of ABMR effectively. Especially, episodes of acute ABMR may not respond to this protocol. Both regimens were not able to completely eradicate the existing DSA. In the bortezomib group, a sustained decrease in DSAmax levels was predictive for better graft survival. Therefore, sequential HLAab screening for DSA may be useful to identify non-responders. In future, new strategies including the combination of both substances and the application of higher doses seems to be necessary in order to further improve the prognosis of ABMR.
